Comment on "Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial".

Yu, Shaorong; Feng, Jifeng

Yu, Shaorong; Feng, Jifeng.

Afiliação

Yu S; Department of Medical Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, People's Republic of China.
Feng J; Department of Medical Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, People's Republic of China. Electronic address: jifeng_feng@163.com.

J Thorac Oncol ; 19(1): 173-174, 2024 01.

Article em En | MEDLINE | ID: mdl-38185511

Assuntos

Neoplasias Pulmonares; Humanos; Neoplasias Pulmonares/tratamento farmacológico; Anticorpos Monoclonais

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pulmonares Limite: Humans Idioma: En Revista: J Thorac Oncol Ano de publicação: 2024 Tipo de documento: Article País de publicação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google